Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. (XETRA: DUL) is trading at €225.90, about ₹24,603 at today's EUR/INR rate, as of 30 Sep 2026, 3:04 AM ET, up 1.39% today. Indian residents can buy Alnylam Pharmaceuticals from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
€225.90
Today's high
€225.90
52 week low
€171.96
52 week high
€426.10
DUL opened at €225.90, closed previously at €222.80, and has traded between €171.96 and €426.10 over the past 52 weeks.
About
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies based on ribonucleic acid interference (RNAi) technology. The company's diverse pipeline of experimental RNAi therapeutics addresses a variety of serious conditions, including inherited genetic disorders, cardiometabolic ailments, hepatic infectious diseases, and diseases affecting the central nervous system (CNS) and eyes. Currently, Alnylam markets several key products: ONPATTRO (patisiran), an injection for adults suffering from polyneuropathy due to hereditary transthyretin-mediated amyloidosis; GIVLAARI, approved for the treatment of acute hepatic porphyria (AHP) in adults; and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial offerings, Alnylam is actively advancing numerous drug candidates. These include givosiran for adolescent AHP, patisiran for transthyretin amyloidosis (ATTR amyloidosis) with cardiomyopathy, and cemdisiran for complement-mediated diseases. Other investigational therapies in development are ALN-AAT02 for AAT deficiency-associated liver disease, ALN-HBV02 for chronic hepatitis B infection, Zilebesiran for hypertension, and ALN-HSD for nonalcoholic steatohepatitis (NASH). Additionally, the company is developing Fitusiran for hemophilia and rare bleeding disorders, Inclisiran for hypercholesterolemia, lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran, which is in Phase 3 clinical trials for ATTR amyloidosis. Alnylam Pharmaceuticals also maintains strategic collaborations, notably with Regeneron Pharmaceuticals, Inc., to identify, develop, and commercialize RNAi therapeutics targeting ocular and CNS diseases, and with Sanofi Genzyme for broader RNAi therapeutic discovery and development. The company also holds licensing and collaboration agreements with several other entities, including Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Founded in 2002, Alnylam Pharmaceuticals, Inc. operates from its headquarters in Cambridge, Massachusetts.
Key statistics
Avg. volume
140.00
Market cap
€30.23B
P/E Ratio
41.65
Price-to-sales ratio
7.08
Enterprise value
$53.62B
Free cash flow yield
0.89%
Debt-to-equity ratio
0.94
Return on equity
39.76%
ROIC
12.58%
Beta
0.27
Dividend yield
0.00%
Last dividend
€0.00
Financial overview
Revenue
$3.71B
Earnings per share
$2.40
Free cash flow
$465.41M
Net profit margin
16.82%
Gross margin
79.72%
EBITDA
$631.48M
Revenue growth
65.20%
Similar securities
This is not an investment recommendation
How to buy Alnylam Pharmaceuticals from India
Indian residents can buy Alnylam Pharmaceuticals shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to EUR.
Search for Alnylam Pharmaceuticals and place an order
Find Alnylam Pharmaceuticals by name or by its ticker, DUL, and choose an order type. Alnylam Pharmaceuticals trades 12:30 pm – 9:00 pm IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your Alnylam Pharmaceuticals position in EUR and INR. Alnylam Pharmaceuticals pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in Alnylam Pharmaceuticals from India
Trading and taxes when buying Alnylam Pharmaceuticals from India
Trading and limits
- Trading hours
- 9:00 am – 5:30 pm CET
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneAlnylam Pharmaceuticals does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
FAQs
Can Indian residents buy Alnylam Pharmaceuticals stock?
Yes. Alnylam Pharmaceuticals (DUL) has been listed on XETRA since 2007, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to EUR. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
How much does one Alnylam Pharmaceuticals share cost in rupees?
One Alnylam Pharmaceuticals share is €225.90 — about ₹24,603 at an EUR/INR rate of 108.91 on 29 Sep 2026. Both the Alnylam Pharmaceuticals price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying Alnylam Pharmaceuticals from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
How are gains on Alnylam Pharmaceuticals shares taxed in India?
Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the EUR/INR rate on the purchase and the sale date, so the rupee move counts alongside the Alnylam Pharmaceuticals price. Paasa issues a capital-gains statement for your return.
Does Alnylam Pharmaceuticals pay a dividend?
No. Alnylam Pharmaceuticals does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade Alnylam Pharmaceuticals from India?
XETRA trades 12:30 pm – 9:00 pm IST in Indian time. The window shifts to 1:30 pm – 10:00 pm IST when Germany is on standard time. Orders can only execute during that window.
Is Alnylam Pharmaceuticals a Germany company, and does that change how it is taxed?
Alnylam Pharmaceuticals trades on XETRA in EUR, but the company is domiciled in United States. Alnylam Pharmaceuticals trades as an ordinary share listed directly in Germany, not a depositary receipt. Your India-side capital-gains treatment is the same either way.
Do I have to declare Alnylam Pharmaceuticals shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Alnylam Pharmaceuticals holding, its cost and its closing value.
How do I sell Alnylam Pharmaceuticals and bring the money back to India?
You sell during market hours (12:30 pm – 9:00 pm IST) and the proceeds settle in EUR in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.
Does the rupee rate affect what I make on Alnylam Pharmaceuticals?
Yes. Alnylam Pharmaceuticals is priced in EUR, so your rupee outcome combines the EUR move with the EUR/INR move between the day you remit and the day you convert back. Both directions are reflected in the capital-gains statement Paasa issues.